Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2015 (2015), Article ID 232818, 8 pages
http://dx.doi.org/10.1155/2015/232818
Review Article

Peroxisome Proliferator-Activated Receptor-γ in Thyroid Autoimmunity

1Department of Clinical and Experimental Medicine, University of Pisa, Via Savi 10, 56126 Pisa, Italy
2Department of Clinical & Experimental Medicine, Endocrinology, University of Messina, Viale Gazzi, Padiglione H, 4 Piano, 98125 Messina, Italy

Received 25 October 2014; Revised 24 December 2014; Accepted 7 January 2015

Academic Editor: Richard P. Phipps

Copyright © 2015 Silvia Martina Ferrari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. N. Pearce, A. P. Farwell, and L. E. Braverman, “Thyroiditis,” The New England Journal of Medicine, vol. 348, no. 26, pp. 2646–2655, 2003, Erratum in: The New England Journal of Medicine, vol. 349, no. 6, pp. 620, 2003. View at Publisher · View at Google Scholar
  2. B. Vaidya and S. H. Pearce, “Diagnosis and management of thyrotoxicosis,” British Medical Journal, vol. 349, article 5128, 2014. View at Publisher · View at Google Scholar
  3. C. G. P. Roberts and P. W. Ladenson, “Hypothyroidism,” The Lancet, vol. 363, no. 9411, pp. 793–803, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. I. B. Pedersen, P. Laurberg, N. Knudsen et al., “An increased incidence of overt hypothyroidism after iodine fortification of salt in Denmark: a prospective population study,” The Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 8, pp. 3122–3127, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Rizzo, R. T. Rossi, O. Bonaffini et al., “Increased annual frequency of Hashimoto's thyroiditis between years 1988 and 2007 at a cytological unit of Sicily,” Annales d'Endocrinologie, vol. 71, no. 6, pp. 525–534, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. D. S. A. McLeod and D. S. Cooper, “The incidence and prevalence of thyroid autoimmunity,” Endocrine, vol. 42, no. 2, pp. 252–265, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Antonelli, S. M. Ferrari, A. Corrado, A. Di Domenicantonio, and P. Fallahi, “Autoimmune thyroid disorders,” Autoimmunity Reviews, vol. 14, no. 2, pp. 174–180, 2015. View at Publisher · View at Google Scholar
  8. J. A. Lankhaar, W. R. de Vries, J. A. Jansen, P. M. J. Zelissen, and F. J. G. Backx, “Impact of overt and subclinical hypothyroidism on exercise tolerance: a systematic review,” Research Quarterly for Exercise and Sport, vol. 85, no. 3, pp. 365–389, 2014. View at Publisher · View at Google Scholar
  9. S. Tognini, G. Pasqualetti, V. Calsolaro, A. Polini, and F. Monzani, “Cognitive function and quality of life in mild thyroid hormone deficiency,” Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, vol. 8, no. 2, pp. 124–134, 2014. View at Publisher · View at Google Scholar
  10. W. M. Wiersinga, “Quality of life in Graves' ophthalmopathy,” Best Practice & Research: Clinical Endocrinology & Metabolism, vol. 26, no. 3, pp. 359–370, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Estcourt, A. G. Quinn, and B. Vaidya, “Quality of life in thyroid eye disease: impact of quality of care,” European Journal of Endocrinology, vol. 164, no. 5, pp. 649–655, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. T. H. Brix and L. Hegedüs, “Twin studies as a model for exploring the aetiology of autoimmune thyroid disease,” Clinical Endocrinology, vol. 76, no. 4, pp. 457–464, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Laurberg, T. Jørgensen, H. Perrild et al., “The Danish investigation on iodine intake and thyroid disease, DanThyr: status and perspectives,” European Journal of Endocrinology, vol. 155, no. 2, pp. 219–228, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Bartalena, C. Marcocci, M. L. Tanda et al., “Cigarette smoking and treatment outcomes in Graves ophthalmopathy,” Annals of Internal Medicine, vol. 129, no. 8, pp. 632–635, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Carlé, I. B. Pedersen, N. Knudsen et al., “Smoking cessation is followed by a sharp but transient rise in the incidence of overt autoimmune hypothyroidism—a population-based, case-control study,” Clinical Endocrinology, vol. 77, no. 5, pp. 764–772, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Drutel, F. Archambeaud, and P. Caron, “Selenium and the thyroid gland: more good news for clinicians,” Clinical Endocrinology, vol. 78, no. 2, pp. 155–164, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Desailloud and D. Hober, “Viruses and thyroiditis: an update,” Virology Journal, vol. 6, article 5, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. T. P. Giordano, L. Henderson, O. Landgren et al., “Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus,” Journal of the American Medical Association, vol. 297, no. 18, pp. 2010–2017, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Indolfi, S. Stagi, E. Bartolini et al., “Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection,” Clinical Endocrinology, vol. 68, no. 1, pp. 117–121, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Bartolomé, E. Rodríguez-Iñigo, P. Quadros et al., “Detection of hepatitis C virus in thyroid tissue from patients with chronic HCV infection,” Journal of Medical Virology, vol. 80, no. 9, pp. 1588–1594, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. J. T. Blackard, L. Kong, A. K. Huber, and Y. Tomer, “Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis,” Thyroid, vol. 23, no. 7, pp. 863–870, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Menconi, A. Hasham, and Y. Tomer, “Environmental triggers of thyroiditis: hepatitis C and interferon-α,” Journal of Endocrinological Investigation, vol. 34, no. 1, pp. 78–84, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. M. J. Simmonds, “GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis,” Nature Reviews Endocrinology, vol. 9, no. 5, pp. 277–287, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Dittmar and G. J. Kahaly, “Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up,” The Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 7, pp. 2983–2992, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. T. C. M. V. Robazzi and L. F. F. Adan, “Autoimmune thyroid disease in patients with rheumatic diseases,” Revista Brasileira de Reumatologia, vol. 52, no. 3, pp. 417–430, 2012. View at Google Scholar · View at Scopus
  26. N. Alfaris, R. Curiel, S. Tabbara, and M. S. Irwig, “Autoimmune thyroid disease and Sjögren syndrome,” Journal of Clinical Rheumatology, vol. 16, no. 3, pp. 146–147, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Namjou, J. A. Kelly, J. Kilpatrick et al., “Linkage at 5q14.3-15 in multiplex systemic lupus erythematosus pedigrees stratified by autoimmune thyroid disease,” Arthritis and Rheumatism, vol. 52, no. 11, pp. 3646–3650, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. W. Scherbaum, “Pathogenesis of autoimmune thyroiditis,” Nuklerarmedizin, vol. 16, pp. 241–249, 1993. View at Google Scholar
  29. E. Fiore, T. Rago, M. Scutari et al., “Papillary thyroid cancer, although strongly associated with lymphocitic infiltration on histology, is only weakly predicted by serum thyroid auto-antibodies in patients with nodular thyroid diseases,” Journal of Endocrinological Investigation, vol. 32, no. 4, pp. 344–351, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Fiore, T. Rago, F. Latrofa et al., “Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine,” Endocrine-Related Cancer, vol. 18, no. 4, pp. 429–437, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Boi, L. Minerba, M. L. Lai et al., “Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules,” Journal of Endocrinological Investigation, vol. 36, no. 5, pp. 313–320, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Antonelli, P. Fallahi, S. M. Ferrari et al., “Dedifferentiated thyroid cancer: a therapeutic challenge,” Biomedicine & Pharmacotherapy, vol. 62, no. 8, pp. 559–563, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. M. E. Greene, B. Blumberg, O. W. McBride et al., “isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping,” Gene Expression, vol. 4, no. 4-5, pp. 281–299, 1995. View at Google Scholar · View at Scopus
  34. L. Michalik, J. Auwerx, J. P. Berger et al., “International union of pharmacology. LXI. Peroxisome proliferator-activated receptors,” Pharmacological Reviews, vol. 58, no. 4, pp. 726–741, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Fajas, D. Auboeuf, E. Raspé et al., “The organization, promoter analysis, and expression of the human PPARgamma gene,” The Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. J. R. Jones, C. Barrick, K.-A. Kim et al., “Deletion of PPARγ in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 17, pp. 6207–6212, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Li, Y. Qi, T. H. W. Huang, J. Yamahara, and B. D. Roufogalis, “Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-α/-γ activator properties,” Diabetes, Obesity and Metabolism, vol. 10, no. 1, pp. 10–17, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. T. G. Kroll, P. Sarraf, L. Pecciarini et al., “PAX8-PPARγ1 fusion in oncogene human thyroid carcinoma,” Science, vol. 289, no. 5483, pp. 1357–1360, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Martin, “Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components,” Mutation Research, vol. 690, no. 1-2, pp. 57–63, 2010. View at Publisher · View at Google Scholar
  40. L. Klotz, S. Schmidt, R. Heun, T. Klockgether, and H. Kölsch, “Association of the PPARγ gene polymorphism Pro12Ala with delayed onset of multiple sclerosis,” Neuroscience Letters, vol. 449, no. 1, pp. 81–83, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. J. J. Regieli, J. W. Jukema, P. A. Doevendans et al., “PPARγ variant influences angiographic outcome and 10-year cardiovascular risk in male symptomatic coronary artery disease patients,” Diabetes Care, vol. 32, no. 5, pp. 839–844, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Pascual, A. L. Fong, S. Ogawa et al., “A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma,” Nature, vol. 437, no. 7059, pp. 759–763, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Koufany, D. Moulin, A. Bianchi et al., “Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis,” Arthritis Research & Therapy, vol. 10, no. 1, article R6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Aprahamian, R. G. Bonegio, C. Richez et al., “The peroxisome proliferator-activated receptor γ agonist rosiglitazone ameliorates murine lupus by induction of adiponectin,” Journal of Immunology, vol. 182, no. 1, pp. 340–346, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Kawai, T. Masaki, S. Doi et al., “PPAR-γ agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-β,” Laboratory Investigation, vol. 89, no. 1, pp. 47–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Hyong, V. Jadhav, S. Lee et al., “Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents,” Brain Research, vol. 1215, pp. 218–224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. J. H. Yu, K. H. Kim, and H. Kim, “SOCS 3 and PPAR-γ ligands inhibit the expression of IL-6 and TGF-β1 by regulating JAK2/STAT3 signaling in pancreas,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 4, pp. 677–688, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Faveeuw, S. Fougeray, V. Angeli et al., “Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells,” FEBS Letters, vol. 486, no. 3, pp. 261–266, 2000. View at Publisher · View at Google Scholar · View at Scopus
  50. J. S. Welch, M. Ricote, T. E. Akiyama, F. J. Gonzalez, and C. K. Glass, “PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6712–6717, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. J. J. Bright, C. C. Walline, S. Kanakasabai, and S. Chakraborty, “Targeting PPAR as a therapy to treat multiple sclerosis,” Expert Opinion on Therapeutic Targets, vol. 12, no. 12, pp. 1565–1575, 2008. View at Publisher · View at Google Scholar · View at Scopus
  52. J. D. Lewis, G. R. Lichtenstein, J. J. Deren et al., “Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial,” Gastroenterology, vol. 134, no. 3, pp. 688–695, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. A. J. Krentz and P. S. Friedmann, “Type 2 diabetes, psoriasis and thiazolidinediones,” International Journal of Clinical Practice, vol. 60, no. 3, pp. 362–363, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. D. Panigrahy, S. Singer, L. Q. Shen et al., “PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis,” The Journal of Clinical Investigation, vol. 110, no. 7, pp. 923–932, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. R. Belfort, S. A. Harrison, K. Brown et al., “A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis,” The New England Journal of Medicine, vol. 355, no. 22, pp. 2297–2307, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. B. Charbonnel, J. Dormandy, E. Erdmann, M. Massi-Benedetti, and A. Skene, “The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients,” Diabetes Care, vol. 27, no. 7, pp. 1647–1653, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. E. Mannucci, M. Monami, C. Lamanna, G. F. Gensini, and N. Marchionni, “Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials,” Diabetes, Obesity & Metabolism, vol. 10, no. 12, pp. 1221–1238, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. S. E. Nissen, S. J. Nicholls, K. Wolski et al., “Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial,” The Journal of the American Medical Association, vol. 299, no. 13, pp. 1561–1573, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. A. G. Atanasov, J. N. Wang, S. P. Gu et al., “Honokiol: a non-adipogenic PPARγ agonist from nature,” Biochimica et Biophysica Acta: General Subjects, vol. 1830, no. 10, pp. 4813–4819, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. L. Wang, B. Waltenberger, E.-M. Pferschy-Wenzig et al., “Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review,” Biochemical Pharmacology, vol. 92, no. 1, pp. 73–89, 2014. View at Publisher · View at Google Scholar
  61. H. Martin, “Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 690, no. 1-2, pp. 57–63, 2010. View at Publisher · View at Google Scholar
  62. M. G. Belvisi, D. J. Hele, and M. A. Birrell, “Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation,” European Journal of Pharmacology, vol. 533, no. 1–3, pp. 101–109, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. Y. Liu, J. Shi, J. Lu et al., “Activation of peroxisome proliferator-activated receptor-γ potentiates pro-inflammatory cytokine production, and adrenal and somatotropic changes of weaned pigs after Escherichia coli lipopolysaccharide challenge,” Innate Immunity, vol. 15, no. 3, pp. 169–178, 2009. View at Publisher · View at Google Scholar · View at Scopus
  64. N. Marx, F. Mach, A. Sauty et al., “Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ- induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells,” The Journal of Immunology, vol. 164, no. 12, pp. 6503–6508, 2000. View at Publisher · View at Google Scholar · View at Scopus
  65. K. L. Schaefer, S. Denevich, C. Ma et al., “Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-γ ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms,” Inflammatory Bowel Diseases, vol. 11, no. 3, pp. 244–252, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. B. Bertin, L. Dubuquoy, J.-F. Colombel, and P. Desreumaux, “PPAR-gamma in ulcerative colitis: a novel target for intervention,” Current Drug Targets, vol. 14, no. 12, pp. 1501–1507, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. T. Hussell and T. J. Bell, “Alveolar macrophages: plasticity in a tissue-specific context,” Nature Reviews Immunology, vol. 14, no. 2, pp. 81–93, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. E. Fuentes, L. Guzmán-Jofre, R. Moore-Carrasco, and I. Palomo, “Role of PPARs in inflammatory processes associated with metabolic syndrome (Review),” Molecular Medicine Reports, vol. 8, no. 6, pp. 1611–1616, 2013. View at Google Scholar · View at Scopus
  69. K. S. Gustafson, V. A. LiVolsi, E. E. Furth, T. L. Pasha, M. E. Putt, and Z. W. Baloch, “Peroxisome proliferator-activated receptor γ expression in follicular-patterned thyroid lesions: caveats for the use of immunohistochemical studies,” American Journal of Clinical Pathology, vol. 120, no. 2, pp. 175–181, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. K. Kasai, N. Banba, A. Hishinuma et al., “15-Deoxy-Δ12,14-prostaglandin J2 facilitates thyroglobulin production by cultured human thyrocytes,” The American Journal of Physiology—Cell Physiology, vol. 279, no. 6, pp. C1859–C1869, 2000. View at Google Scholar · View at Scopus
  71. L. Y. Mimura, S. M. F. Villares, M. L. R. Monteiro, I. C. Guazzelli, and W. Bloise, “Peroxisome proliferator-activated receptor-γ gene expression in orbital adipose/connective tissues is increased during the active stage of Graves' ophthalmopathy,” Thyroid, vol. 13, no. 9, pp. 845–850, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. W. M. Wiersinga, N. I. Regensburg, and M. P. Mourits, “Differential involvement of orbital fat and extraocular muscles in graves' ophthalmopathy,” European Thyroid Journal, vol. 2, no. 1, pp. 14–21, 2013. View at Publisher · View at Google Scholar
  73. S. Kumar, M. J. Coenen, P. E. Scherer, and R. S. Bahn, “Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy,” The Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 2, pp. 930–935, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. O. E. Okosieme, A. B. Parkes, L. D. K. E. Premawardhana, A. W. Thomas, L. M. Evans, and J. H. Lazarus, “Peripheral cytokine expression in autoimmune thyroiditis: effects of In Vitro modulation by rosiglitazone and dexamethasone,” Thyroid, vol. 16, no. 10, pp. 953–960, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Poncin, A.-C. Gérard, M. Boucquey et al., “Oxidative stress in the thyroid gland: from harmlessness to hazard depending on the iodine content,” Endocrinology, vol. 149, no. 1, pp. 424–433, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. J. R. Groom and A. D. Luster, “CXCR3 ligands: redundant, collaborative and antagonistic functions,” Immunology & Cell Biology, vol. 89, no. 2, pp. 207–215, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Antonelli, M. Rotondi, P. Fallahi et al., “Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing,” Cytokine, vol. 34, no. 1-2, pp. 32–38, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Antonelli, P. Fallahi, S. M. Ferrari et al., “Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study,” Diabetic Medicine, vol. 25, no. 11, pp. 1349–1353, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. S. M. Ferrari, P. Fallahi, C. Mancusi et al., “HCV-related autoimmune disorders in HCV chronic infection,” La Clinica Terapeutica, vol. 164, no. 4, pp. e305–e312, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. E. Y. Lee, Z. H. Lee, and Y. W. Song, “The interaction between CXCL10 and cytokines in chronic inflammatory arthritis,” Autoimmunity Reviews, vol. 12, no. 5, pp. 554–557, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Lacotte, S. Brun, S. Muller, and H. Dumortier, “CXCR3, inflammation, and autoimmune diseases,” Annals of the New York Academy of Sciences, vol. 1173, pp. 310–317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. A. Antonelli, C. Ferri, P. Fallahi et al., “Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis,” European Journal of Endocrinology, vol. 156, no. 4, pp. 431–437, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Antonelli, C. Ferri, P. Fallahi et al., “Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis,” The Journal of Rheumatology, vol. 35, no. 9, pp. 1809–1811, 2008. View at Google Scholar · View at Scopus
  84. A. Antonelli, A. Delle Sedie, P. Fallahi et al., “High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis,” The Journal of Rheumatology, vol. 33, no. 10, pp. 2026–2028, 2006. View at Google Scholar · View at Scopus
  85. R. Su, M.-L. T. Nguyen, M. R. Agarwal et al., “Interferon-inducible chemokines reflect severity and progression in sarcoidosis,” Respiratory Research, vol. 14, article 121, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Antonelli, C. Ferri, P. Fallahi et al., “High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection,” The American Journal of Gastroenterology, vol. 103, no. 10, pp. 2488–2494, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. C. Ferri, A. Antonelli, M. T. Mascia et al., “B-cells and mixed cryoglobulinemia,” Autoimmunity Reviews, vol. 7, no. 2, pp. 114–120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Antonelli, C. Ferri, P. Fallahi, C. Nesti, A. L. Zignego, and M. Maccheroni, “Thyroid cancer in HCV-related mixed cryoglobulinemia patients,” Clinical and Experimental Rheumatology, vol. 20, no. 5, pp. 693–696, 2002. View at Google Scholar · View at Scopus
  89. A. Antonelli, C. Ferri, P. Fallahi et al., “High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis,” Cytokine, vol. 42, no. 1, pp. 137–143, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Antonelli, C. Ferri, P. Fallahi et al., “Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study,” Thyroid, vol. 17, no. 5, pp. 447–451, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. A. Antonelli, C. Ferri, P. Fallahi et al., “Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis,” Metabolism: Clinical and Experimental, vol. 57, no. 9, pp. 1270–1277, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Antonelli, S. M. Ferrari, P. Fallahi et al., “Dysregulation of secretion of CXC α-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-γ agonists,” Endocrine-Related Cancer, vol. 16, no. 4, pp. 1299–1311, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. A. Antonelli, S. M. Ferrari, D. Giuggioli, E. Ferrannini, C. Ferri, and P. Fallahi, “Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases,” Autoimmunity Reviews, vol. 13, no. 3, pp. 272–280, 2014. View at Publisher · View at Google Scholar · View at Scopus
  94. W. Zhu, L. Ye, L. Shen et al., “A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with Graves' ophthalmopathy,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 6, pp. 1999–2007, 2014. View at Publisher · View at Google Scholar
  95. J. Mysliwiec, I. Palyga, M. Kosciuszko, A. Kowalska, and M. Gorska, “Circulating CXCL9 and CXCL10 as markers of activity of graves' orbitopathy during treatment with corticosteroids and teleradiotherapy,” Hormone and Metabolic Research, vol. 44, no. 13, pp. 957–961, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. A. Antonelli, M. Rotondi, S. M. Ferrari et al., “Interferon-γ-inducible α-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-γ agonists,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 2, pp. 614–620, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Antonelli, S. M. Ferrari, P. Fallahi et al., “Monokine induced by interferon gamma (IFNγ) (CXCL9) and IFNγ inducible T-cell α-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-γ agonists,” The Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 5, pp. 1803–1809, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. A. Antonelli, S. M. Ferrari, P. Fallahi et al., “Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone,” Metabolism, vol. 60, no. 2, pp. 277–283, 2011. View at Publisher · View at Google Scholar · View at Scopus
  99. A. Antonelli, S. M. Ferrari, P. Fallahi et al., “Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists,” Cytokine, vol. 50, no. 3, pp. 260–267, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Antonelli, S. M. Ferrari, A. Corrado et al., “Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPARγ,” Autoimmunity Reviews, vol. 13, no. 11, pp. 1160–1166, 2014. View at Publisher · View at Google Scholar
  101. K. Starkey, A. Heufelder, G. Baker et al., “Peroxisome proliferator-activated receptor-γ in thyroid eye disease: contraindication for thiazolidinedione use?” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 1, pp. 55–59, 2003. View at Publisher · View at Google Scholar · View at Scopus
  102. M. Dorkhan, M. Lantz, A. Frid, L. Groop, and B. Hallengren, “Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes,” Clinical Endocrinology, vol. 65, no. 1, pp. 35–39, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. E. Pawlak-Adamska, J. Daroszewski, M. Bolanowski et al., “PPARg2 Ala12 variant protects against Graves' orbitopathy and modulates the course of the disease,” Immunogenetics, vol. 65, no. 7, pp. 493–500, 2013. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Alevizaki, E. Mantzou, A. Cimponeriu, K. Saltiki, G. Philippou, and W. Wiersinga, “The Pro 12Ala PPARγ gene polymorphism: possible modifier of the activity and severity of thyroid-associated orbitopathy (TAO),” Clinical Endocrinology, vol. 70, no. 3, pp. 464–468, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. D. J. Graham, R. Ouellet-Hellstrom, T. E. Macurdy et al., “Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone,” Journal of the American Medical Association, vol. 304, no. 4, pp. 411–418, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. P. Shah and S. Mudaliar, “Pioglitazone: side effect and safety profile,” Expert Opinion on Drug Safety, vol. 9, no. 2, pp. 347–354, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. E. Erdmann and R. Wilcox, “Pioglitazone and mechanisms of CV protection,” QJM, vol. 103, no. 4, pp. 213–228, 2010. View at Publisher · View at Google Scholar · View at Scopus